Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell line.

Posted by on in 2016
  • Font size: Larger Smaller
  • Hits: 781
  • Print

Borhani K1Mohabati Mobarez A2Khabiri AR3Behmanesh M4Khoramabadi N12016. Microb Pathog. 97:231-5. doi: 10.1016/j.micpath.2016.06.004. Epub 2016 Jun 2.

1Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
2Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address:
3Diagnosis Biotechnology Unit, Pasteur Institute of Iran, Alborz, Iran. Electronic address:
4Department of Genetic, Faculty of Life Sciences, Tarbiat Modares University, Tehran, Iran.


Helicobacter pylori is a major human pathogen related to gastric adenocarcinoma and gastroduodenal diseases. Treatment of H. pylori infections is complicated by the rise of antibiotic resistance, necessitating investigation of alternative therapies. One such alternative is passive immunization by oral administration of antibacterial immunoglobulin. In the present study, chicken immunoglobulin (IgY) was used for passive immunotherapy against a major virulence factor of H. pylori, namely recombinant HP-Nap protein. Recombinant HP-Nap was prepared and used to immunize hens. IgY was purified from the eggs by polyethylene glycol precipitation method with a total IgY-HP-NAP yield of 30 mg per egg. The inhibitory effect of specific IgY on H. pylori attachment was investigated in AGS cell line infected by the bacteria. The results demonstrate the potent effect of IgY- HP-NAP in inhibition of H. pylori attachment to the AGS cells.


Alternative therapy; Gastrointestinal disease; HP-NAP; IgY; Immunotherapy

[Indexed for MEDLINE]
Last modified on